Armstrong, April
González-Cantero, Alvaro
Khattri, Saakshi
Muzy, Guilherme
Malatestinic, William N.
Lampropoulou, Anastasia
Feely, Meghan
See, Sophia Kyoungah
Mert, Can
Blauvelt, Andrew http://orcid.org/0000-0002-2633-985X
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 24 January 2024
Accepted: 29 February 2024
First Online: 23 March 2024
Declarations
:
: April Armstrong has received grants or contracts from, and served as a consultant, speaker and/or investigator for: AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, EPI Health, Incyte, LEO Pharma, UCB, Janssen, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Sun, Sanofi, and Regeneron; has participated on data safety monitoring or advisory boards for: Boehringer Ingelheim and Parexel; and has been elected to the Board of Directors for the American Academy of Dermatology. Alvaro González-Cantero has served as a consultant and speaker for: AbbVie, Almirall, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, L’Oreal, MSD, Novartis, and UCB Pharma; and has received grants or contracts from: Almirall, Celgene, and LEO Pharma. Saakshi Khattri has received grants or contracts from, and/or served as a consultant and/or speaker for: AbbVie, Bristol Myers Squibb, Eli Lilly and Company, Incyte, Janssen, LEO Pharma, Pfizer, Regeneron, Sanofi, and UCB Pharma. Guilherme Muzy has received honoraria and/or consulting fees from: AbbVie, Eli Lilly and Company, Sanofi, Novartis, Janssen, and Pfizer; has been a speaker for: AbbVie, Eli Lilly, Sanofi, Novartis, Janssen and Pfizer; and has participated on data safety monitoring or advisory boards for: Abbvie, Eli Lilly, Sanofi, Janssen, and Pfizer. William N. Malatestinic, Anastasia Lampropoulou, and Sophia Kyoungah See are employees and shareholders of Eli Lilly and Company. Meghan Feely is associate staff at Mount Sinai Hospital, Mount Sinai West, and Mount Sinai Morningside; a current employee and shareholder of Eli Lilly and Company; and has received consulting, travel, or speaker fees from: American Academy of Dermatology, Aerolase, Castle Biosciences, CeraVe—L'Oréal, DREAM USA, Galderma Aesthetics, Glow Recipe, La Roche-Posay—L'Oréal, Revian, Sonoma Pharmaceuticals, Sun Pharma, and Suneva Medical. Can Mert is a contractor of HaaPACs GmbH and conducted statistical analysis for this project on behalf of Eli Lilly and Company. Andrew Blauvelt has served as a speaker (received honoraria) for: Eli Lilly and Company, Pfizer, and UCB Pharma; served as a scientific adviser (received honoraria) for: AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, ASLAN Pharmaceuticals, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO pharma, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor; and has acted as a clinical study investigator (institution has received clinical study funds) for: AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, UCB Pharma, and Ventyx.
: All study protocols, amendments, and consent documentation were approved by the necessary central or local institutional review boards (IRB) and/or ethics committees. All patients were required to give written informed consent prior to participation in UNCOVER-2, UNCOVER-3, IXORA-R, IXORA-S, or PSoHO. Each study was conducted in compliance with local laws and regulations and according to International Conference on Harmonization, Good Clinical Practice guidelines, and the Helsinki Declaration of 1964, and its later amendments. We confirm that the necessary central or local IRB and/or ethics committee approvals have been obtained for each study. Approvals can be provided on request.